Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 501

1.

Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers.

Cole AP, Lu C, Krimphove MJ, Szymaniak J, Sun M, Fletcher SA, Lipsitz SR, Mahal BA, Nguyen PL, Choueiri TK, Kibel AS, Haider AH, Trinh QD.

J Natl Compr Canc Netw. 2019 Sep 1;17(9):1049-1058. doi: 10.6004/jnccn.2019.7296.

PMID:
31487683
2.

Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma.

Braun DA, Ishii Y, Walsh AM, Van Allen EM, Wu CJ, Shukla SA, Choueiri TK.

JAMA Oncol. 2019 Sep 5. doi: 10.1001/jamaoncol.2019.3158. [Epub ahead of print] No abstract available.

PMID:
31486842
3.

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.

Dudani S, Graham J, Wells JC, Bakouny Z, Pal SK, Dizman N, Donskov F, Porta C, de Velasco G, Hansen A, Iafolla M, Beuselinck B, Vaishampayan UN, Wood LA, Liow E, Yan F, Yuasa T, Bjarnason GA, Choueiri TK, Heng DYC.

Eur Urol. 2019 Aug 22. pii: S0302-2838(19)30609-8. doi: 10.1016/j.eururo.2019.07.048. [Epub ahead of print]

PMID:
31445844
4.

The Immune Landscape of Cancer.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I.

Immunity. 2019 Aug 20;51(2):411-412. doi: 10.1016/j.immuni.2019.08.004. No abstract available.

5.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators.

Lancet Oncol. 2019 Aug 16. pii: S1470-2045(19)30413-9. doi: 10.1016/S1470-2045(19)30413-9. [Epub ahead of print] Erratum in: Lancet Oncol. 2019 Aug 21;:.

PMID:
31427204
6.

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Graham J, Wells JC, Donskov F, Lee JL, Fraccon A, Pasini F, Porta C, Bowman IA, Bjarnason GA, Ernst DS, Rha SY, Beuselinck B, Hansen A, North SA, Kollmannsberger CK, Wood LA, Vaishampayan UN, Pal SK, Choueiri TK, Heng DYC.

Eur Urol Oncol. 2019 Apr 4. pii: S2588-9311(19)30041-0. doi: 10.1016/j.euo.2019.03.007. [Epub ahead of print]

PMID:
31411994
7.

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.

George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK.

Oncologist. 2019 Aug 9. pii: theoncologist.2019-0316. doi: 10.1634/theoncologist.2019-0316. [Epub ahead of print]

PMID:
31399500
8.

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J.

Circulation. 2019 Jul 2;140(2):80-91.

PMID:
31390169
9.

PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.

Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles T, Wang E, Huang Y, Freeman GJ, Choueiri TK, Signoretti S.

Clin Cancer Res. 2019 Aug 1. doi: 10.1158/1078-0432.CCR-19-1135. [Epub ahead of print]

PMID:
31371341
10.

Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals.

Tan WS, Berg S, Cole AP, Krimphove M, Marchese M, Lipsitz SR, Nabi J, Sammon JD, Choueiri TK, Kibel AS, Sun M, Chang S, Trinh QD.

JNCI Cancer Spectr. 2019 Feb 1;3(1):pkz003. doi: 10.1093/jncics/pkz003. eCollection 2019 Mar.

11.

Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer.

Tan WS, Krimphove MJ, Cole AP, Marchese M, Berg S, Lipsitz SR, Löppenberg B, Nabi J, Abdollah F, Choueiri TK, Kibel AS, Sooriakumaran P, Trinh QD.

Clin Genitourin Cancer. 2019 Jun 19. pii: S1558-7673(19)30035-7. doi: 10.1016/j.clgc.2019.06.008. [Epub ahead of print]

PMID:
31303561
12.

Contemporary national trends in prostate cancer risk profile at diagnosis.

Fletcher SA, von Landenberg N, Cole AP, Gild P, Choueiri TK, Lipsitz SR, Trinh QD, Kibel AS.

Prostate Cancer Prostatic Dis. 2019 Jun 24. doi: 10.1038/s41391-019-0157-y. [Epub ahead of print]

PMID:
31235801
13.

Sex specific associations in genome wide association analysis of renal cell carcinoma.

Laskar RS, Muller DC, Li P, Machiela MJ, Ye Y, Gaborieau V, Foll M, Hofmann JN, Colli L, Sampson JN, Wang Z, Bacq-Daian D, Boland A, Abedi-Ardekani B, Durand G, Le Calvez-Kelm F, Robinot N, Blanche H, Prokhortchouk E, Skryabin KG, Burdett L, Yeager M, Radojevic-Skodric S, Savic S, Foretova L, Holcatova I, Janout V, Mates D, Rascu S, Mukeria A, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Świątkowska B, Benhamou S, Cancel-Tassin G, Cussenot O, Trichopoulou A, Riboli E, Overvad K, Panico S, Ljungberg B, Sitaram RT, Giles GG, Milne RL, Severi G, Bruinsma F, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Beane Freeman LE, Koutros S, Albanes D, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Chow WH, Moore LE, Choueiri TK, Wood C, Johansson M, McKay JD, Brown KM, Rothman N, Lathrop MG, Deleuze JF, Wu X, Brennan P, Chanock SJ, Purdue MP, Scelo G.

Eur J Hum Genet. 2019 Oct;27(10):1589-1598. doi: 10.1038/s41431-019-0455-9. Epub 2019 Jun 23.

PMID:
31231134
14.

A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.

Harding JJ, Zhu AX, Bauer TM, Choueiri TK, Drilon A, Voss MH, Fuchs CS, Abou-Alfa GK, Wijayawardana SR, Wang XA, Moser BA, Uruñuela A, Wacheck V, Bendell JC.

Clin Cancer Res. 2019 Sep 1;25(17):5202-5211. doi: 10.1158/1078-0432.CCR-18-4010. Epub 2019 May 29.

PMID:
31142504
15.

Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.

Hanna N, Trinh QD, Seisen T, Vetterlein MW, Sammon J, Preston MA, Lipsitz SR, Bellmunt J, Menon M, Choueiri TK, Abdollah F.

Eur Urol Oncol. 2018 May;1(1):83-90. doi: 10.1016/j.euo.2018.03.001. Epub 2018 May 15.

PMID:
31100232
16.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.

PMID:
31079938
17.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up.

Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF.

Ann Oncol. 2019 May 3. pii: mdz127. doi: 10.1093/annonc/mdz127. [Epub ahead of print]

18.

Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Stukalin I, Wells JC, Graham J, Yuasa T, Beuselinck B, Kollmansberger C, Ernst DS, Agarwal N, Le T, Donskov F, Hansen AR, Bjarnason GA, Srinivas S, Wood LA, Alva AS, Kanesvaran R, Fu SYF, Davis ID, Choueiri TK, Heng DYC.

Curr Oncol. 2019 Apr;26(2):e175-e179. doi: 10.3747/co.26.4595. Epub 2019 Apr 1.

19.

Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?

Cole AP, Krasnova A, Ramaswamy A, Friedlander DF, Fletcher SA, Sun M, Choueiri TK, Weissman JS, Kibel AS, Trinh QD.

Prostate Cancer Prostatic Dis. 2019 Apr 12. doi: 10.1038/s41391-019-0138-1. [Epub ahead of print]

PMID:
30980025
20.

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME.

Future Oncol. 2019 May;15(15):1683-1695. doi: 10.2217/fon-2018-0951. Epub 2019 Apr 10.

PMID:
30968729
21.

A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis.

Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, Leshchiner ES, Viswanathan VS, Signoretti S, Choueiri TK, Boehm JS, Wagner BK, Doench JG, Clish CB, Clemons PA, Schreiber SL.

Nat Commun. 2019 Apr 8;10(1):1617. doi: 10.1038/s41467-019-09277-9.

22.

State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era.

Bakouny Z, Flippot R, Braun DA, Lalani AA, Choueiri TK.

Eur Urol Focus. 2019 Feb 28. pii: S2405-4569(19)30049-5. doi: 10.1016/j.euf.2019.02.014. [Epub ahead of print] Review.

PMID:
30827939
23.

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC.

Lancet Oncol. 2019 Apr;20(4):581-590. doi: 10.1016/S1470-2045(18)30907-0. Epub 2019 Feb 28.

PMID:
30827746
24.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK.

N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.

PMID:
30779531
25.

Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.

Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ.

Future Oncol. 2019 Mar;15(9):929-941. doi: 10.2217/fon-2018-0745. Epub 2019 Jan 28.

26.

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Pignon JC, Jegede O, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Choueiri TK, Wu CJ, Atkins MB, McDermott DF, Signoretti S.

Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. doi: 10.1158/1078-0432.CCR-18-3206. Epub 2019 Jan 22.

PMID:
30670497
27.

Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1.

Chakraborty S, Balan M, Flynn E, Zurakowski D, Choueiri TK, Pal S.

Oncogenesis. 2019 Jan 15;8(2):7. doi: 10.1038/s41389-018-0116-9.

28.

Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?

Cole AP, Fletcher SA, Berg S, Nabi J, Mahal BA, Sonpavde GP, Nguyen PL, Lipsitz SR, Sun M, Choueiri TK, Preston MA, Kibel AS, Trinh QD.

Cancer. 2019 Apr 15;125(8):1319-1329. doi: 10.1002/cncr.31926. Epub 2019 Jan 11.

PMID:
30633323
29.

Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign.

Friedlander DF, von Landenberg N, Löppenberg B, Noldus J, Lipsitz SR, Cole AP, Abdollah F, Nguyen PL, Choueiri TK, Kibel AS, Trinh QD.

J Urol. 2019 Apr;201(4):728-734. doi: 10.1097/JU.0000000000000006.

PMID:
30633112
30.

The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study.

Johansson M, Carreras-Torres R, Scelo G, Purdue MP, Mariosa D, Muller DC, Timpson NJ, Haycock PC, Brown KM, Wang Z, Ye Y, Hofmann JN, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Garnier JG, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Radojevic-Skodric S, Ognjanovic S, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Benhamou S, Cancel-Tassin G, Cussenot O, Weiderpass E, Ljungberg B, Tumkur Sitaram R, Häggström C, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Andreotti G, Beane Freeman LE, Koutros S, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Wilson KM, Gaziano JM, Sesso HD, Freedman ND, Parker AS, Eckel-Passow JE, Huang WY, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, Choueiri TK, Lathrop GM, Deleuze JF, Gunter M, McKay JD, Wu X, Houlston RS, Chanock SJ, Relton C, Richards JB, Martin RM, Davey Smith G, Brennan P.

PLoS Med. 2019 Jan 3;16(1):e1002724. doi: 10.1371/journal.pmed.1002724. eCollection 2019 Jan.

31.

Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.

Nassar AH, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen EM, Preston M, Dong F, Bellmunt J, Mouw KW, Choueiri TK, Sonpavde G, Kwiatkowski DJ.

Clin Cancer Res. 2019 Apr 15;25(8):2458-2470. doi: 10.1158/1078-0432.CCR-18-3147. Epub 2018 Dec 28.

PMID:
30593515
32.

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.

Boilève A, Carlo MI, Barthélémy P, Oudard S, Borchiellini D, Voss MH, George S, Chevreau C, Landman-Parker J, Tabone MD, Chism DD, Amin A, Bilen MA, Bosse D, Coulomb-L'hermine A, Su X, Choueiri TK, Tannir NM, Malouf GG.

J Immunother Cancer. 2018 Dec 27;6(1):159. doi: 10.1186/s40425-018-0482-z.

33.

Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL.

Eur Urol. 2019 Jan;75(1):35-41. doi: 10.1016/j.eururo.2018.08.033. Epub 2018 Oct 24.

PMID:
30554605
34.

Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.

McClintock TR, von Landenberg N, Cole AP, Lipsitz SR, Gild P, Sun M, Fletcher SA, Roghmann F, Menon M, Nguyen PL, Noldus J, Choueiri TK, Kibel AS, Trinh QD.

Ann Surg Oncol. 2019 Jan;26(1):297-305. doi: 10.1245/s10434-018-7035-z. Epub 2018 Nov 14.

PMID:
30430324
35.

Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer.

Berg S, Cole AP, Krimphove MJ, Nabi J, Marchese M, Lipsitz SR, Noldus J, Choueiri TK, Kibel AS, Trinh QD.

Eur Urol. 2019 Apr;75(4):552-555. doi: 10.1016/j.eururo.2018.10.032. Epub 2018 Nov 10.

PMID:
30420255
36.

Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.

Voss MH, Reising A, Cheng Y, Patel P, Marker M, Kuo F, Chan TA, Choueiri TK, Hsieh JJ, Hakimi AA, Motzer RJ.

Lancet Oncol. 2018 Dec;19(12):1688-1698. doi: 10.1016/S1470-2045(18)30648-X. Epub 2018 Nov 8.

PMID:
30416077
37.

Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals.

Krimphove MJ, Fletcher SA, Cole AP, Berg S, Sun M, Lipsitz SR, Mahal BA, Nguyen PL, Choueiri TK, Kibel AS, Kluth LA, Weissman JS, Trinh QD.

J Urol. 2019 Apr;201(4):735-741. doi: 10.1016/j.juro.2018.10.024.

PMID:
30414956
38.

Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma.

McKay RR, Bossé D, Choueiri TK.

J Clin Oncol. 2018 Oct 29:JCO2018790253. doi: 10.1200/JCO.2018.79.0253. [Epub ahead of print]

PMID:
30372392
39.

Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light.

Albiges L, Flippot R, Rioux-Leclercq N, Choueiri TK.

J Clin Oncol. 2018 Oct 29:JCO2018792531. doi: 10.1200/JCO.2018.79.2531. [Epub ahead of print]

PMID:
30372389
40.

Use of Preventive Health Services Among Cancer Survivors in the U.S.

Gupta S, Cole AP, Marchese M, Wang Y, Speed JM, Fletcher SA, Nabi J, Berg S, Lipsitz SR, Choueiri TK, Chang SL, Kibel AS, Uhlig A, Trinh QD.

Am J Prev Med. 2018 Dec;55(6):830-838. doi: 10.1016/j.amepre.2018.07.021. Epub 2018 Oct 21.

PMID:
30352719
41.

Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies.

Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Stühler V, Wells JC, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Chin Heng DY.

Clin Genitourin Cancer. 2019 Feb;17(1):65-71. doi: 10.1016/j.clgc.2018.09.006. Epub 2018 Sep 12.

PMID:
30341028
42.

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.

Lalani AA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, Wood C, Bex A.

Eur Urol. 2019 Jan;75(1):100-110. doi: 10.1016/j.eururo.2018.10.010. Epub 2018 Oct 13. Review.

PMID:
30327274
43.

Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, Choueiri TK, Heng DYC.

Cancer. 2018 Sep 15;124(18):3677-3683. doi: 10.1002/cncr.31595. Epub 2018 Oct 11.

PMID:
30307610
44.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
45.

Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy.

Berg S, Cole AP, Fletcher SA, Pucheril D, Nabi J, Lipsitz SR, Chang SL, Sun M, Noldus J, Harshman LC, Choueiri TK, Trinh QD.

Urol Oncol. 2018 Sep;36(9):400.e15-400.e22. doi: 10.1016/j.urolonc.2018.06.005.

PMID:
30274640
46.

Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].

Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ.

Eur J Cancer. 2018 Nov;103:287. doi: 10.1016/j.ejca.2018.09.022. Epub 2018 Sep 27. No abstract available.

47.

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.

Hamieh L, Choueiri TK, Ogórek B, Khabibullin D, Rosebrock D, Livitz D, Fay A, Pignon JC, McDermott DF, Agarwal N, Gao W, Signoretti S, Kwiatkowski DJ.

PLoS Genet. 2018 Sep 26;14(9):e1007679. doi: 10.1371/journal.pgen.1007679. eCollection 2018 Sep.

48.
49.

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.

Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bossé D, Van Allen EM, Choueiri TK, Rosenberg JE.

Br J Cancer. 2018 Sep;119(6):707-712. doi: 10.1038/s41416-018-0261-0. Epub 2018 Sep 17.

50.

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.

Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY, Park SH, Geertsen PF, Gross-Goupil M, Grande E, Suarez C, Markby DW, Arroyo A, Dean M, Choueiri TK, George D.

Br J Cancer. 2018 Sep;119(6):663-669. doi: 10.1038/s41416-018-0164-0. Epub 2018 Sep 10.

Supplemental Content

Loading ...
Support Center